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ABSTRACT 
Aim: DNA gyrase and topoisomerase IV are essential bacterial enzymes, and in the fight 
against bacterial resistance, they are important targets for the development of novel antibacterial 
drugs. Results: Building from our first generation of 4,5,6,7-tetrahydrobenzo[d]thiazole-based 
DNA gyrase inhibitors, we designed and prepared an optimized series of analogs that show 
improved inhibition of DNA gyrase and topoisomerase IV from Staphylococcus aureus and 
Escherichia coli, with IC50 values in the nanomolar range. Importantly, these inhibitors also 
show improved antibacterial activity against Gram-positive strains. Conclusions: The most 
promising inhibitor, 29, is active against Enterococcus faecalis, Enterococcus faecium and S. 
aureus wild-type and resistant strains, with MICs between 4 μg/mL and 8 μg/mL, which 



















Inhibition of growth of Staphylococcus aureus
E. coli gyrase IC50: 0.056 µM
S. aureus gyrase IC50: 3.7 µM
MRSA MIC: 8 µg/mL













Many clinically important pathogenic microorganisms have become resistant to the currently 
available antibiotics. In 2017, the World Health Organization published a list of priority 
pathogens for which new antibiotic treatments are urgently needed [1, 2]. The reasons for this 
development of multidrug-resistant microorganisms include inappropriate prescribing and 
consuming of antibiotics, false dose regimens, and extensive agricultural use of antimicrobials. 
The available treatment options for infections caused by multidrug-resistant bacteria have also 
worsened because of a substantial reduction in newly approved antibacterials over the past two 
decades [3]. Fortunately, clinicians have recognized bacterial resistance as one of the major 
human health threats, and antibacterial drug discovery that targets the multidrug-resistant 
strains has recently gained more research interest. To overcome the issue of antibiotic 
resistance, there is the need for the development of antibacterial agents with new mechanisms 
of action [4] and with multi-targeting drugs that simultaneously inhibit different bacterial 
targets, for which the bacterial development of target-based resistance will be slower [5]. 
Bacterial topoisomerases have important roles in replication of DNA through their 
catalysis of modifications to its topological state during replication [6, 7]. Topoisomerase 
inhibition leads to complete loss of cell viability and bacterial cell death [7, 8]. DNA gyrase and 
topoisomerase IV are type IIA topoisomerases that show high structural and sequence similarity 
and are composed of two subunits, GyrA and ParC, respectively, and GyrB and ParE, which 
contain the ATPase active site [9]. These two enzymes are validated and attractive targets for 
antibacterial drug discovery [10, 11]. The catalytic GyrA and ParC subunits are inhibited by the 
therapeutically-used fluoroquinolone class of antibiotics [12, 13]. Moreover, inhibition of the 
ATP-binding GyrB and ParE subunits is also a promising strategy for the development of new 
antibacterial drugs [9, 10, 14]. For example, the aminocoumarin antibiotic novobiocin (1; 
Figure 1) was previously used in therapy, although it was withdrawn because of resistance 
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development and the discovery of safer and more effective antibacterial drugs [10]. 
Furthermore, novel DNA gyrase and topoisomerase IV inhibitors that belong to different 
chemical classes with distinct modes of action are now in clinical development (e.g., 
gepotidacin, 2 [15]; zoliflodacin, 3 [16]; Figure 1) [11]. The structural similarities between 
DNA gyrase and topoisomerase IV offer the opportunity to design dual-targeting inhibitors for 
which the bacterial target-based resistance will develop more slowly compared to compounds 
that inhibit a single target. Besides, there is no cross-resistance between inhibitors that bind to 
the catalytic (e.g., fluoroquinolones) and ATPase (e.g., novobiocin) subunits of DNA gyrase 
and topoisomerase IV [17].  
As the targeting of the ATP-binding site of bacterial DNA gyrase can be associated with 
selectivity issues in terms of human ATP-binding enzymes, determination of the selectivity 
toward structurally similar enzymes is of great importance [18]. Selectivity of GyrB and ParE 
inhibitors against eukaryotic topoisomerase II can be achieved by exploiting the important 
differences between the amino-acid residues that comprise the inhibitor binding sites of the 
human and bacterial topoisomerases. Moreover, although seldom reported, the selectivity 
profiles against human protein kinases are usually good [9, 18, 19]. The potential drawback of 
targeting the ATP-binding site of DNA gyrase still remains toxicity, which was an issue 
associated with many of the newly discovered DNA gyrase inhibitors in the past [10], and lack 
of increasing the concentration of enzyme-DNA cleavage complexes, which is the mechanism 
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Figure 1. DNA gyrase inhibitor novobiocin, and two novel DNA gyrase and topoisomerase IV inhibitors in clinical 
development. 
Our first GyrB inhibitors were discovered through virtual screening of a designed library 
of marine alkaloid analogs, among which the 4,5,6,7-tetrahydrobenzo[d]thiazoles were shown 
to be the most potent [21]. Following our initial discovery and optimization of the virtual 
screening hits [21], we designed and prepared several series of N-phenylpyrrolamides as a new 
structural class of potent GyrB inhibitors with antibacterial activities [22-25]. In addition, the 
benzothiazole-2,6-diamine scaffold was introduced in the place of the 4,5,6,7-
tetrahydrobenzo[d]thiazole, to obtain analogs with low nanomolar inhibition of Escherichia coli 
DNA gyrase and improved inhibition of E. coli topoisomerase IV [26]. To further explore the 
structure-activity relationships (SARs) of the 4,5,6,7-tetrahydrobenzo[d]thiazoles, a series of 
»reversed« analogs and ring-opened inhibitors was also synthesized. However, these 
compounds showed only (sub)micromolar DNA gyrase inhibition and poor antibacterial 
activities due to the loss of the important cation-π interactions in the binding site [27]. A 
common feature of all of these inhibitors is the pyrrole moiety, which is also found in some 
other structural classes of GyrB inhibitors with antibacterial properties, such as the natural 
antibiotics clorobiocin (4; Figure 2) [28] and kibdelomycin [29], as well as synthetic inhibitors 
like aminothiazoles (5, AZD5099; Figure 2) [30] and N-phenylpyrrolamides (6; Figure 2) [25]. 
In addition to the pyrrole-containing compounds, potent GyrB and ParE inhibitors were also 
identified in other structural classes, such as ethyl ureas, which are mainly active against Gram-
positive bacteria [31] (7; Figure 2), and tricyclic inhibitors [19] (8; Figure 2), which are also 
































































Figure 2. Representative GyrB and ParE inhibitors of natural and synthetic origins. 
Although the first generation of 4,5,6,7-tetrahydrobenzo[d]thiazole inhibitors showed 
potent E. coli DNA gyrase inhibition, their activities against E. coli topoisomerase IV and S. 
aureus DNA gyrase and topoisomerase IV were more than 100-fold weaker. This thus resulted 
in poor antibacterial activities against the tested Gram-positive bacterial strains. The 
compounds were also not active against the tested Gram-negative strains, which was mainly 
attributed to their poor penetration and active efflux from the bacterial cytoplasm [21]. By 
measuring the volumes of the hydrophobic pockets of E. coli and S. aureus GyrB and ParE, 
where the pyrrolamide moiety of inhibitors is bound in the available crystal structures, we noted 
that the pocket volume in E. coli GyrB is larger compared to the other three enzymes. Therefore, 
poor inhibition of S. aureus DNA gyrase and S. aureus and E. coli topoisomerase IV might be 
explained by steric clashes of the 4,5-dibromo- and 4,5-dichloropyrrolamide moieties in the 
hydrophobic pocket. The aim of the present study was thus to further explore the SARs around 
the 4,5,6,7-tetrahydrobenzo[d]thiazole scaffold, to improve the inhibition of DNA gyrase and 
topoisomerase IV, which would also result in improved antibacterial activities.  
2. EXPERIMENTAL SECTION 
2.1. Materials and methods 
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The chemicals were obtained from Acros Organics (Geel, Belgium), Sigma-Aldrich (St. Louis, 
MO, USA), TCI Europe N.V. (Zwijndrecht, Belgium), and Apollo Scientific (Stockport, UK), 
and were used without further purification. Analytical TLC was performed on silica gel Merck 
60 F254 plates (0.25 mm), using visualization with UV light and spray reagents. Column 
chromatography was carried out on silica gel 60 (particle size, 240-400 mesh). HPLC analyses 
were performed on: (i) Agilent Technologies 1100 instrument with a UV-VIS detector 
(G1365B), a thermostat (G1316A), an autosampler (G1313A) and a C18 column (Eclipse Plus; 
5 µm, 4.6 × 150 mm; Agilent); (ii) Thermo Scientific Dionex Ultimate 3000 Binary Rapid 
Separation LC System (Thermo Fisher Scientific, Waltham, MA, USA) with an autosampler, a 
binary pump system, a photodiode array detector, a thermostated column compartment and a 
C18 column (Zorbax Extend; 3.5 µm, 4.6 × 150 mm; Agilent). The following gradient elution 
method was used with mobile phases A (0.1% trifluoroacetic acid in water) and B (acetonitrile): 
0-16 min, 95%-5% A; 16-21 min, 5% A. The flow rate was 1.0 mL/min, and the injection 
volume was 20 μL. All of the tested compounds were ≥95% pure by HPLC. Melting points 
were determined on a Reichert hot-stage microscope, and are uncorrected. 1H and 13C NMR 
spectra were recorded at 400 MHz and 100 MHz, respectively, on an AVANCE III 400 
spectrometer (Bruker Corporation, Billerica, MA, USA) in DMSO-d6, CDCl3, or MeOD-d4 
solutions, with TMS as the internal standard. Mass spectra were obtained using a Q-TOF 
Premier mass spectrometer (Micromass, Waters, Manchester, UK) or an expression compact 
mass spectrometer (Advion Inc., Ithaca, USA) or Exactive™ Plus Orbitrap mass spectrometer 
(Thermo Fischer Scientific Inc., Waltham, MA 02451 USA). Optical rotations were measured 
on a polarimeter (241 MC; Perkin-Elmer). The reported values for specific rotation were the 




2.2. Determination of inhibitory activities against E. coli and S. aureus DNA gyrase and 
topoisomerase IV 
The assays for the determination of IC50 values against E. coli and S. aureus DNA gyrase and 
topoisomerase IV were performed according to the previously reported procedures [21]. 
2.3. Determination of inhibitory activities against human DNA topoisomerase II 
The inhibitory activities against human DNA topoisomerase II were determined in an assay on 
streptavidin-coated 96-well microtiter plates (Inspiralis, Thermo Scientific Pierce). First, the 
plates were rehydrated with buffer (20 mM Tris-HCl, 0.01% [w/v] BSA, 0.05% [v/v] Tween 
20, 137 mM NaCl, pH 7.6), and then the biotinylated oligonucleotide was immobilized. After 
washing off the unbound oligonucleotide, the enzyme assay was performed. The reaction 
volume of 30 µL in buffer (50 mM Tris-HCl, 10 mM MgCl2, 125 mM NaCl, 5 mM 
dithiothreitol, 0.1 µg/mL albumin, 1 mM ATP, pH 7.5) contained 1.5 U human DNA 
topoisomerase II, 0.75 µg supercoiled pNO1 plasmid, and 3 µL of the inhibitor solution in 10% 
dimethylsulfoxide (DMSO) containing 0.008% (v/v) Tween 20. The reaction solutions were 
incubated at 37 °C for 30 min. Then, TF buffer (50 mM NaOAc, 50 mM NaCl, 50 mM MgCl2, 
pH 5.0) was added to terminate the enzymatic reaction. After an additional incubation for 30 
min at room temperature, during which the biotin–oligonucleotide–plasmid triplex was formed, 
the unbound plasmid was washed off using TF buffer, and Diamond Dye was added in T10 
buffer (10 mM Tris-HCl, 1 mM EDTA, pH 8.0). The fluorescence was measured with a 
microplate reader (BioTek Synergy H4; excitation, 485 nm; emission, 537 nm). The initial 
screening was at 100 μM or 10 μM inhibitor. For the most active inhibitors, the IC50 values 
were determined using seven concentrations of the tested compounds. The GraphPad Prism 6 
software was used to calculate the IC50 values. The results are reported as the mean values of 
three independent measurements. Etoposide was used as the positive control (IC50, 59 µM).  
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2.4. Determination of antibacterial activities 
Clinical microbiology control strains of E. faecalis (ATCC 29212), S. aureus (ATCC 25923), 
E. coli (ATCC 25922), P. aeruginosa (ATCC 27853), E. faecium (ATCC 700221), and 
vancomycin-intermediate S. aureus (ATCC 700699) were obtained from Microbiologics Inc. 
(St. Cloud, MN, USA). Methicillin-resistant S. aureus (ATCC 43300), and S. aureus (ATCC 
29213) strains, which were used for additional testing (Table 6), were obtained from the 
University of Szeged (Hungary). Single-gene knock-out mutant strains of E. coli JW5503 (tolC 
knock-out) and JD17464 (lpxC knock-out) were obtained from the E. coli collection of the 
National BioResource Project at the National Institute of Genetics (Japan) [32]. E. coli K-12 
MG1655 lines carrying the clinically most commonly observed fluoroquinolone resistance 
mutations (GyrA S83L, D87N, D87Y; ParC S80I, E84G) and the combinations thereof were 
constructed in-house with the aid of the genome engineering method pORTMAGE, described 
in detail in previous papers [33, 34]. To determine the antibacterial activities, broth 
microdilution assays were carried out in 96-well plates following the Clinical and Laboratory 
Standards Institute guidelines. For selected compounds, the MICs were determined by 
construction of the dose–response curves (from at least two independent experiments, each with 
three replicates per concentration). 
2.5. Molecular modeling 
2.5.1. Molecular docking 
The crystal structure of E. coli DNA gyrase B in complex with adenylyl-imidodiphosphate 
(PDB entry: 1EI1 [35]) was used in the docking experiments, as retrieved from the Protein Data 
Bank. The docking calculations were carried out using the AutoDock 4.2 software [36]. In all 
of the calculations, the following parameters were used: the initial population of trial ligands 
comprised 250 individuals; the maximum number of generations was set to 270,000; the 
maximum number of energy evaluations was 10.0 ×106; and all of the other run parameters 
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were maintained at their default settings. The docked conformations that resulted were clustered 
into families considering the backbone root mean square deviation. 
2.5.2. Refinement of the anchoring and QTAIM analysis 
After the docking calculations, the leading lowest energy structures were optimized at the M06-
2X/631G(d) level using quantum mechanics/ molecular mechanics calculations. The inhibitors 
and the side chains of the residues that had at least one heavy atom within 4 Å from the ligand 
molecule (i.e., first shell residues) were incorporated into the high-level QM layer using the 
M06-2X/631G(d) method. The chosen cut-off value resulted from a compromise between 
computational cost and efficiency [37, 38]. The remainder of the system was included in the 
low-level MM layer using the Assisted Model Building with Energy Refinement (AMBER) 
force field. The MM parameters that were absent in the standard AMBER force field were 
included from the generalized AMBER force field [39]. These calculations were carried out 
using the Gaussian 09 package [40]. Then, the optimized geometry for each inhibitor–GyrB 
complex was used as the input for the QTAIM analysis [41], which was carried out using the 
Multiwfn software [42], with the wave functions generated at the M06-2X/6-31G(d) level. 
3. RESULTS AND DISCUSSION 
3.1 Design 
Novel 4,5,6,7-tetrahydrobenzo[d]thiazoles were designed based on the known crystal structures 
of inhibitors bound to the 43-kDa N-terminal fragment of E. coli GyrB, as described previously 
by our research group (PDB codes: 4ZVI, 5L3J) [23, 26]. The binding site of GyrB comprises 
a well-defined hydrophobic pocket that consists of amino-acid residues Val43, Ala47, Val71, 
Ile78, Val120, and Val167 (E. coli GyrB numbering), and the carboxylate group of Asp73, 
which together with a conserved water molecule, forms a network of hydrogen bonds with the 
pyrrole-2-carboxamide moiety of the ligand that mimics the binding of the adenine ring of ATP 
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[21]. Finally, additional salt bridge interactions with the Arg136 guanidine group and cation-π 
interactions between the planar aromatic ring and the Arg76 side chain within the Glu50-Arg76 
salt bridge are possible in the binding site (Figure 3).  
 
Figure 3. Interactions of representative compound I of the first generation of 4,5,6,7-tetrahydrobenzo[d]thiazole-
based inhibitors in the E. coli GyrB ATP-binding site, as predicted by molecular docking. Hydrophobic interactions 
are shown in yellow, hydrogen bonds as dashed arrows and negative charge is shown in red. 
In the second generation 4,5,6,7-tetrahydrobenzo[d]thiazoles, we retained the pyrrole-
2-carboxamide moiety to form hydrogen bonds with the binding site residues, as shown in 
Figure 3, while examining the steric fit of differently substituted pyrroles of varying sizes (Table 
1, type I compounds) with the hydrophobic pocket of GyrB and ParE of E. coli and S. aureus. 
As the acidity of the pyrrole NH group was shown to have an important role in the binding of 
compounds through an influence on the strength of the hydrogen bond with the Asp73 side 
chain [21], we incorporated different numbers of chloro and/or bromo substituents with 
negative inductive effects at positions 3, 4, and 5 of the pyrrole ring. In addition, a methyl group 
was introduced at position 5 of the pyrrole moiety, to increase the hydrophobic interactions 
within the enzyme pyrrolamide binding pocket. While modifying the pyrrole moiety, the 
malonyl substituent on the amino group at position 2 of the 4,5,6,7-tetrahydrobenzo[d]thiazole 
core was kept constant (Figure 3) [21]. 
In the second stage, we fixed the pyrrolamide moiety by using either a 4,5-dibromo- or 
3,4-dichloro-5-methylpyrrolamide and introduced different functionalities at position 2 of the 
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4,5,6,7-tetrahydrobenzo[d]thiazole core, which were selected to achieve additional polar 
interactions (i.e., hydrogen bonds and/or ionic interactions) with the positively charged side-
chain guanidine groups of Arg76 and/or Arg136. The 1,3,4-oxadiazol-2-one ring was 
introduced as a carboxylic acid bioisostere, as it can form similar interactions with Arg136. At 
the same time, it is less acidic, and therefore we expected it to improve the cell-wall penetration 
of the compounds, and consequently their antibacterial activities [25]. Aromatic rings in 
compounds of the type II and III series (Tables 3, 4) were introduced to form cation-π 
interactions and/or hydrogen bonds with Arg136, which would improve enzyme inhibition. In 
all type I-III compounds, only the (S)-enantiomers were prepared, as the (R)-enantiomers were 
previously shown to be weaker inhibitors of DNA gyrase than their (S)-antipodes [21]. 
 
3.2. Chemistry 
All of the compounds were synthesized from the parent (S)-4,5,6,7-tetrahydrobenzo[d]thiazole-
2,6-diamine (9; Scheme 1), which represents the central scaffold of the designed inhibitors and 
was obtained according to the published procedure [43].  All of the substituted pyrroles used 
for the preparation of type I compounds were also synthesized according to the reported 
procedures [44]. Pyrrole-2-carboxylic acids were coupled to the 6-amino group of the central 
scaffold by 1-ethyl-3-(3-(dimethylamino)propyl)-carbodiimide (EDC)/1-hydroxybenzotriazole 
(HOBt)-promoted amide-bond formation, while the 2-trichloroacetylpyrroles were attached by 
heating the reaction mixtures in the presence of a base (Scheme 1), to obtain compounds 10-19. 
In the next step, acylation of the 2-amino group of 10-19 with methyl 3-chloro-3-oxopropanoate 
or ethyl 2-chloro-2-oxoacetate in the presence of triethylamine gave esters 20-30, which were 
hydrolyzed with 1 M NaOH to the carboxylic acids 31-41. Esters 20 and 26 were treated with 
hydrazine hydrate in dry ethanol, to obtain the hydrazides 42 and 43 (Scheme 2). Compound 
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43 was then cyclized to the 1,3,4-oxadiazol-2-one derivative 44 (Scheme 2) in the presence of 
1,1'-carbonyldiimidazole (CDI). 
Sulfonamides 50 and 51 were prepared as shown in Scheme 3. The tert-butylcarbamate 
45 was first reacted with methanesulfonyl chloride to obtain the sulfonamide 46, which was 
then deprotected by acidolysis using HCl generated in situ by addition of acetyl chloride to 
methanol. The compound obtained, 48, was then reacted with 2,2,2-trichloro-1-(4,5-dibromo-
1H-pyrrol-2-yl)ethan-1-one or 3,4-dichloro-5-methyl-1H-pyrrole-2-carboxylic acid, to yield 
compounds 50 and 51, respectively. Additionally, compound 45 was treated with ethyl 
isocyanate, to obtain the Boc-protected ethylurea 47. This Boc-protected ethylurea was 
converted to the amine 49 by acidolysis, which after coupling with 2,2,2-trichloro-1-(4,5-
dibromo-1H-pyrrol-2-yl)ethan-1-one gave the ethylurea 52. Alternatively, its 3,4-dichloro-5-
methyl-1H-pyrrole-based counterpart, 53, was prepared by reacting amine 15 with ethyl 
isocyanate (Scheme 4). Compound 54 was prepared by acetylation of 15, while amides 55-62 
and 65-70 were prepared from 10 or 15 by EDC/HOBt or 2-(1H-benzotriazole-1-yl)-1,1,3,3-
tetramethylaminium tetrafluoroborate (TBTU)-promoted coupling with aromatic carboxylic 
acids (Scheme 4). Alkaline hydrolysis of 61 and 62 gave 63 and 64, respectively, while 











13 (R1=Me, R2=Cl, R3=H)
14 (R1=Me, R2=Br, R3=H)
15 (R1=Me, R2=R3=Cl)
16 (R1=Me, R2=R3=Br)
17 (R1=Me, R2=Cl, R3=Br)




















20 (R1=R2=Br, R3=H, R4=Me, n=1)
21 (R1=R2=R3=H, R4=Me, n=1)
22 (R1=Me, R2=R3=H, R4=Me, n=1)
23 (R1=Me, R2=Cl, R3=H, R4=Me, n=1)
24 (R1=Me, R2=Br, R3=H, R4=Me, n=1)
25 (R1=Me, R2=R3=Cl, R4=Et, n=0)
26 (R1=Me, R2=R3=Cl, R4=Me, n=1)
27 (R1=Me, R2=R3=Br, R4=Me, n=1)
28 (R1=Me, R2=Cl, R3=Br, R4=Me, n=1)
29 (R1=Me, R2=Br, R3=Cl, R4=Me, n=1)
30 (R1=CH2OEt, R2=R3=Cl, R4=Me, n=1)
c
31 (R1=R2=Br, R3=H, R4=H, n=1)
32 (R1=R2=R3=H, R4=H, n=1)
33 (R1=Me, R2=R3=H, R4=H, n=1)
34 (R1=Me, R2=Cl, R3=H, R4=H, n=1)
35 (R1=Me, R2=Br, R3=H, R4=H, n=1)
36 (R1=Me, R2=R3=Cl, R4=H, n=0)
37 (R1=Me, R2=R3=Cl, R4=H, n=1)
38 (R1=Me, R2=R3=Br, R4=H, n=1)
39 (R1=Me, R2=Cl, R3=Br, R4=H, n=1)
40 (R1=Me, R2=Br, R3=Cl, R4=H, n=1)
41 (R1=CH2OEt, R2=R3=Cl, R4=H, n=1)
Scheme 1. Reagents and conditions. (a) For 10-14 and 16: corresponding 2,2,2-trichloro-1-(1H-pyrrol-2-yl)ethan-
1-one, Na2CO3, DMF, 40 °C, 4 h; for 15 and 17-19: corresponding pyrrole-2-carboxylic acid, EDC, HOBt, NMM, 
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DMF, r.t., 18 h. (b) For 20-24 and 26-30: methyl 3-chloro-3-oxopropanoate, Et3N, 1,4-dioxane, r.t., 18 h; for 25: 














































































50 (R1=R2=Br, R3=H, R4=SO2Me)
51 (R1=Me, R2=R3=Cl, R4=SO2Me)
52 (R1=R2=Br, R3=H, R4=CONHEt)
R4R1 R1 d
Scheme 3. Reagents and conditions. (a) For 46: methanesulfonyl chloride, pyridine, 0 °C, 18 h. (b) For 47: ethyl 
isocyanate, CHCl3, r.t., 18 h. (c) Acetyl chloride, MeOH, 0 °C, 1 h, then r.t., 18 h. (d) For 50 and 52: 2,2,2-trichloro-
1-(4,5-dibromo-1H-pyrrol-2-yl)ethan-1-one, Na2CO3, DMF, 40 °C, 4 h; for 51: 3,4-dichloro-5-methyl-1H-pyrrole-




















53 (R1=Me, R2=R3=Cl, R4=NHEt)
54 (R1=Me, R2=R3=Cl, R4=Me)
55 (R1=R2=Br, R3=H, R4=1H-imidazole-4-yl)










61 (R1=R2=Br, R3=H, R4=Me)
62 (R1=Me, R2=R3=Cl, R4=Me) d
63 (R1=R2=Br, R3=H, R4=H)
64 (R1=Me, R2=R3=Cl, R4=H)
57 (R1=R2=Br, R3=H, R4=pyridine-4-yl)
58 (R1=Me, R2=R3=Cl, R4=pyridine-4-yl)
59 (R1=R2=Br, R3=H, R4=pyridine-3-yl)














65 (R1=R2=Br, R3=H, R4=COMe)
66 (R1=Me, R2=R3=Cl, R4=COMe)
67 (R1=R2=Br, R3=H, R4=CONHEt)
68 (R1=Me, R2=R3=Cl, R4=CONHEt)
69 (R1=R2=Br, R3=H, R4=COOtBu)
70 (R1=Me, R2=R3=Cl, R4=COOtBu)
71 (R1=R2=Br, R3=H, R4=H)
e
a or b or c
Scheme 4. Reagents and conditions. (a) For 55, 57, 59-62, 65-70: carboxylic acid, EDC, HOBt, NMM, DMF; for 
56 and 58: carboxylic acid, TBTU, Et3N, CH2Cl2, r.t., 24 h. (b) For 53: ethyl isocyanate, CHCl3, r.t., 18 h. (c) For 
54: acetyl chloride, Et3N, 1,4-dioxane, r.t., 18 h. (d) 1 M NaOH, MeOH/H2O, r.t., 24 h. (e) Acetyl chloride, MeOH, 




3. 3. In vitro enzyme inhibition 
All of these final compounds (i.e., 20-44, 50-71) were evaluated for their in vitro inhibitory 
activities against E. coli DNA gyrase using the DNA gyrase supercoiling assay. With the 
exception of some weakly active compounds, all of these inhibitors were also tested in a DNA 
supercoiling assay using S. aureus DNA gyrase, and in a DNA relaxation assay using 
topoisomerase IV from E. coli and S. aureus. The results obtained are presented in Tables 1-3 
as residual activities of the enzymes at 10 µM of the tested compound, or as IC50 values for the 
more potent compounds.  
 
Table 1. Inhibition of Escherichia coli and Staphylococcus aureus DNA gyrase and topoisomerase IV by the 













Compound R1 R2 n 
DNA gyrase  
IC50 [μM] or RA [%]a 
Topoisomerase IV  
IC50 [μM] or RA [%]a 
E. coli S. aureus E. coli S. aureus 



























Me 1 IC50: 0.60 ± 0.19 IC50: 31 ± 23 
IC50: 230 ± 
120 






Et 0 IC50: 0.23 ± 0.05 
IC50: 0.71 ± 
0.32 

























































H 1 IC50: 0.44 ± 0.39 IC50: 7.3 ± 6.2 
IC50: 190 ± 
50 







H 0 IC50: 0.044 ± 0.040 
IC50: 0.43 ± 
0.32 
IC50: 210 ± 
20 







H 1 IC50: 0.022 ±0.002 
IC50: 0.56 ± 
0.22 














H 1 IC50: 0.026 ± 0.019 
IC50: 0.61 ± 
0.11 
RA: 80 







H 1 IC50: 0.016 ± 0.003 IC50: 1.6 ± 0.1 IC50: 24 ± 15 









H 1 RA: 82 n.t. RA: 100 RA: 98 
aRA, residual activity of the enzyme at 10 μM tested compound 
bNB, novobiocin was used as positive control. 
cn.t., not tested. 
ddata published previously [21]. 
Type I compounds (Table 1) were designed to explore the differences in the 
hydrophobic pockets of DNA gyrase and topoisomerase IV from E. coli and S. aureus [21], and 
to investigate the SARs by varying the hydrophobic character of the pyrrole moiety and the 
acidity of the pyrrole NH group, which was shown to interact with the Asp73 side chain (Figure 
3). In these type I compounds, 13 analogs showed E. coli DNA gyrase inhibition with IC50 
values <0.5 μM, and with six of these <0.1 μM. These six were therefore more potent than the 
positive control novobiocin (IC50, 0.17 μM) as well as our previously published 4,5-
dibromopyrrole-based compounds 20 and 31 [21]. The most potent compound was 40, with an 
IC50 of 0.016 μM against E. coli DNA gyrase, and which displayed good inhibition of all four 
of these enzymes, with IC50 values of 1.6 μM, 24 μM, and 0.73 μM against S. aureus DNA 
gyrase, and E. coli and S. aureus topoisomerase IV, respectively.  
Extensive variations of the substituents on the pyrrole moiety revealed details of the 
available chemical space inside the hydrophobic pocket of all four of these investigated 
enzymes. Compounds 21, 22, 32, and 33, containing an unsubstituted pyrrole moiety or only a 
methyl group on the pyrrole ring, were devoid of inhibitory activity, probably because weak 
hydrophobic interactions are formed in the hydrophobic pocket. On the other hand, analogs 
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with an ethoxymethyl substituent at position 5 of the pyrrole (compounds 30 and 41) were too 
bulky to fit into the pocket, and were therefore also inactive. This is in agreement with the 
pyrrolamide pocket volume measurements and with our previous results [21, 23], where an 
indole moiety at this position was also unfavorable.  
A combined quantum mechanics/ molecular mechanics quantum theory of atoms in 
molecules (QTAIM) study was performed to rationalize the observed SARs of these type I 
compounds. QTAIM calculations were performed as they enable evaluation of the molecular 
interactions that stabilize different ligand–enzyme complexes in detail [45-47]. We thus studied 
how the introduction of a methyl group and halogen atoms on the pyrrole ring influenced the 
strengths of interactions between the pyrrole NH and the side chain carboxylate group of Asp73 
(NH ••• OAsp73). Table 2 shows the ρ(r) values, which represent a measure of the hydrogen bond 
strength, of the NH ••• OAsp73 interactions for compounds 31-35, 37, and 38. The 4,5-dibromo 
substitution on the pyrrole ring in 31 resulted in significant increase in the strength of the NH 
••• OAsp73 interaction compared to the unsubstituted pyrrole in 32 (Table 2). In contrast, 
introduction of an electron-donating methyl group at position 5 of the pyrrole moiety in 33 
weakened the NH ••• OAsp73 hydrogen bond. This weakening effect of the 5-methyl group on 
the strength of the NH ••• OAsp73 interaction can be compensated for by the introduction of 
halogen atoms at positions 3 and 4 of the pyrrole moiety (compounds 34, 35, 37, 38; Table 2). 
As the pyrrole moiety is located inside the hydrophobic pocket of the E. coli DNA gyrase ATP-
binding site, which is formed by residues Val43, Ala47, Val71, and Val120, the methyl group 
and halogen atoms can form a large number of hydrophobic contacts (Supporting Information, 
Figures S1, S2). Taken together, the cumulative effects of several hydrophobic interactions and 
the NH ••• OAsp73 hydrogen bond strength have important effects on the E. coli DNA gyrase 
inhibition. In general, the introduction of two halogen atoms at positions 3 and 4 of the pyrrole 
ring improved the E. coli DNA gyrase inhibition due to the increased numbers of hydrophobic 
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interactions and the increased strength of the NH ••• OAsp73 hydrogen bond. The correlation 
obtained between the experimental IC50 values for 31-35, 37, and 38 and Σρ(r) is high, as shown 
in Supporting Information, Figure S3. 
Table 2. Hydrogen bond strengths between the pyrrole NH and the Asp73 side-chain carboxylate group (NH ••• 
OAsp73) obtained from the quantum theory of atoms in molecules calculations.  








ρ(r), atomic units (a.u.) 
For all of these type I compounds, acids 31-41 were more potent E. coli DNA gyrase 
inhibitors than their corresponding methyl or ethyl ester counterparts 20-30, as they can form 
salt-bridge interactions with the guanidine group of the Arg136 side chain in addition to the 
hydrogen bond(s) formed in the case of the esters, which has also been observed previously [21, 
23]. The inhibitory activities against S. aureus DNA gyrase were weaker, which confirmed the 
hypothesis of the more occlusive hydrophobic pocket in S. aureus compared to E. coli GyrB 
[21]. The most potent inhibitors of S. aureus DNA gyrase were 36 and 37, which contain the 
3,4-dichloro-5-methyl-1H-pyrrole moiety with a smaller methyl substituent at position 5 
compared to the 4,5-dibromopyrrole-containing compound 31, which is a weak S. aureus DNA 
gyrase inhibitor (Table 1). By substitution of the chlorine atom at position 3 of the pyrrole 
moiety of compound 37 with a bromine atom, the inhibition of S. aureus DNA gyrase remained 
similar (compound 39), while a bromine substituent at position 4 reduced the activity to a 
greater extent (compound 40). It can thus be concluded that S. aureus DNA gyrase tolerates 
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methyl or chloro substituents at positions 4 and 5 of the pyrrole ring, while larger substituents 
lead to a loss of inhibitory activity. Inhibition of topoisomerase IV by these type I compounds 
was weak, although on the other hand, it was improved in some cases (e.g., compound 40, with 
IC50 values of 24 μM and 0.73 μM against E. coli and S. aureus topoisomerase IV, respectively) 
compared to the parent compound 31 (IC50 values of 74 μM and 76 μM against E. coli and S. 
aureus topoisomerase IV, respectively) (Table 1).  
Table 3. Inhibition of Escherichia coli and Staphylococcus aureus DNA gyrase and topoisomerase IV by the 
4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine derivatives containing different moieties at 2-amino group (type 








Compound R1 R2 
DNA gyrase  
IC50 [μM] or RA [%]a 
Topoisomerase IV  
IC50 [μM] or RA [%]a 
E. coli S. aureus E. coli S. aureus 






















IC50: 0.047 ± 0.011 
IC50: 0.54 ± 
0.32 












































































































































IC50: 0.36 ± 0.10 n.t. n.t. n.t. 
aRA, Residual activity of the enzyme at 10 μM concentration of the tested compound. 
bNB, novobiocin was used as positive control. 
cn.t., not tested. 
For the type II compounds (Table 3), the effects of the replacement of the malonyl group 
by different aliphatic and aromatic moieties that can form hydrogen bonds with Arg76 and/or 
Arg136 were investigated. In general, compounds based on 4,5-dibromopyrrole (42, 50, 52, 55, 
57, 59, 61, 63) and 3,4-dichloro-5-methylpyrrole (43, 44, 51, 53, 54, 56, 58, 60, 62, 64) had 
similar inhibitory potencies against E. coli DNA gyrase, but were typically weaker inhibitors 
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of this enzyme than most of the malonyl-based compounds in Table 1. The most potent type II 
compounds were hydrazides 42 and 43, with E. coli DNA gyrase IC50 values of 0.084 μM and 
0.047 μM, respectively. These two compounds showed improved inhibition in comparison to 
their ester counterparts 20 and 26, but were weaker inhibitors than their corresponding 
carboxylic acids 31 and 37. The hydrazide group is not ionizable under physiological 
conditions, and cannot form ionic interactions with the Arg136 side chain, in contrast to 
carboxylic acids. On the other hand, hydrazide is an H-bond donor/ acceptor group and can still 
interact with the Arg136 guanidine group, which explains the observed inhibition potency. The 
introduction of aromatic rings, such as different imidazole, pyridine, and substituted phenyl 
rings (compounds 55-64), resulted in weaker inhibition of all four of these enzymes compared 
to the malonate derivatives of the type I series. All of the type II compounds were generally 
weak E. coli topoisomerase IV and S. aureus DNA gyrase and topoisomerase IV inhibitors 
(Table 3), which suggests that the moiety attached to the 2-amino group on the 4,5,6,7-
tetrahydrobenzo[d]thiazole also has a very important role in the binding of compounds to the 
enzyme ATP-binding site. The exception is the hydrazide 43, which was among the most potent 
S. aureus DNA gyrase inhibitors of the series, with an IC50 of 0.54 μM (Table 3). 
Table 4. Inhibition of Escherichia coli and Staphylococcus aureus DNA gyrase and topoisomerase IV by the 
4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine derivatives containing the 2-(2-aminothiazol-4-yl)acetyl moiety at 











Compound R1 R2 
DNA gyrase  
IC50 [μM] or RA [%]a 
Topoisomerase IV  
IC50 [μM] or RA [%]a 
E. coli S. aureus E. coli S. aureus 







































IC50: 0.14 ± 0.03 RA: 76 RA: 100 RA: 99 
71 HNBr
Br  
-H IC50: 2.0 ± 0.2 RA: 70 RA: 100 RA: 100 
aRA, residual activity of the enzyme at 10 μM concentration of the tested compound. 
bNB, novobiocin was used as positive control. 
cn.t., not tested. 
The possibility of formation of cation-π interactions with the Arg136 side chain was 
further explored with the aminothiazole derivatives (type III compounds). These analogs had 
generally improved potencies in the E. coli DNA gyrase assay compared to 54, which was 
without the aminothiazole moiety (Tables 3, 4). However, the SAR data suggest that a carbonyl 
bound to 2-amino group of the aminothiazole moiety (compounds 65-70), is important for E. 
coli DNA gyrase inhibition (IC50 between 0.11 μM and 0.34 μM), as compound 71 with a free 
2-amino group was a weak inhibitor, with an IC50 of 2.0 μM (Table 4). All of the type III 
compounds were generally devoid of S. aureus DNA gyrase and topoisomerase IV and E. coli 
topoisomerase IV inhibitory activities (Table 4). 
Selected compounds of types I-III were also tested for their inhibitory activities against 
human topoisomerase IIα, to evaluate their selectivity over the structurally and functionally 
similar human ATP-binding enzyme. Compounds 26, 29, 32, 34, 37, 40, and 41 of the type I 
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series and compound 60 of the type II series were inactive at 100 μM, which showed their 
selectivity for bacterial over human topoisomerases. Type III compounds 68 and 71 inhibited 
human topoisomerase IIα with residual activities of 16% and 68% at 100 μM, but were 
completely inactive at 10 μM. 
3.4. Antibacterial activities 
All of the DNA gyrase and topoisomerase IV inhibitors were tested against two Gram-positive 
(Enterococcus faecalis ATCC 29212, S. aureus ATCC 25923) and two Gram-negative (E. coli 
ATCC 25922, Pseudomonas aeruginosa ATCC 27853) bacterial strains. Additionally, these 
compounds were tested against two E. coli mutant strains, as the lpxC deletion mutant with an 
impaired outer membrane (E. coli JD17464), and the tolC deletion mutant with a defective 
efflux pump (E. coli JW5503). Preliminary tests were carried out at 50 µM, and inhibition of 
growth was measured after 24 h of incubation. The MICs was determined only for the 
compounds with >90% growth inhibition at 50 µM. The results of preliminary screening are 
given in Supporting Information, Table S1, and the MICs for the active compounds are given 
in Table 5. 
Table 5. Minimum inhibitory concentrations of the DNA gyrase and topoisomerase IV inhibitors.  
Compound MIC [μM]a 
 E. faecalis S. aureus  E. coli P. aeruginosa 
 ATCC 29212 ATCC 25923 ATCC 25922 JW5503 JD17464 ATCC 27853 
24 >50 >50 >50 50 (23) >50 >50 
26 50 (22) 50 (22) >50 12.5 (6)  >50 >50 
27 25 (13) 25 (13) >50 12.5 (7) >50 >50 
28 >50 >50 >50 12.5 (6) >50 >50 
29 12.5 (6) >50 >50 12.5 (6) >50 >50 
42 >50 >50b >50 25 (13) >50 >50 
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43 >50 >50 >50 25 (11) >50 >50 
44 50 (24) 50 (24) >50 25 (12) >50 >50 
52 >50 >50 >50 12.5 (6) >50 >50 
55 >50 >50 >50 6.25 (3) >50 >50 
59 >50 >50 >50 12.5 (7) >50 >50 
65 >50 >50 >50 6.25 (4) >50 >50 
67 >50 >50 >50 3.13 (2) >50 >50 
68 50 (28) >50b >50 >50 >50 >50 
Ciprofloxacin 3.0 1.5 0.05 0.015 0.12 3.0 
a Minimum inhibitory concentration that inhibits the growth of bacteria by ≥90%. Values in parentheses are MIC values 
expressed in μg/mL. 
b tested against S. aureus ATCC 29213. 
 
Despite potent inhibition of E. coli DNA gyrase by several of these compounds, and 
especially those from the type I series, they were all devoid of antibacterial activities against 
the tested Gram-negative wild-type E. coli and P. aeruginosa (Supporting Information, Table 
S1, Table 5). These results can be attributed to cell-wall penetration issues of these compounds, 
or to their efflux, as some of them showed improved antibacterial activities against E. coli 
JW5503, which has the defective TolC efflux pump. Compound 67 was the most potent against 
E. coli JW5503, with a MIC of 3.13 μM. From the type I series, the esters were more potent 
than their acid counterparts, while for the types II and III series, the 4,5-dibromopyrrole-based 
compounds appeared to have better activities against E. coli JW5503 than their 3,4-dichloro-5-
methylpyrrole-based analogs (e.g., 59 vs. 60; 67 vs. 68; see Table 5). Most of the antibacterially 
active compounds are potent E. coli DNA gyrase inhibitors that are lipophilic and do not contain 
ionizable groups. 
In general, the antibacterial activities of these tested compounds were better against 
Gram-positive S. aureus and E. faecalis than against Gram-negative E. coli and P. aeruginosa 
(Supporting Information, Table S1, Table 5). The most potent compound against S. aureus was 
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27, with a MIC of 25 µM, while for E. faecalis, 29 had the lowest MIC of the series, at 12.5 
µM (Table 5). Both of these compounds are methyl esters, which were weaker inhibitors of 
DNA gyrase than their carboxylic acid counterparts 38 and 40, respectively. This might be 
explained by the excessive polarity and acidity of the carboxylic acids (Table 1); they therefore 
cannot permeate through the bacterial cell wall, which results in low on-target concentrations 
of these inhibitors. In addition, compounds 24, 27 and 29 showed promising activities also 
against methicillin-resistant S. aureus, vancomycin-intermediate S. aureus, and Enterococcus 
faecium, with MICs between 4 μg/mL and 16 μg/mL (Table 6). Moreover, compounds 27 and 
29 displayed no cross-resistance with fluoroquinolones as they showed improved MIC values 
against fluoroquinolone-resistant strains of E. coli compared to the wild-type (Table 7). In 
conclusion here, the correlation between DNA gyrase/ topoisomerase IV inhibition and 
antibacterial activity against Gram-positive and Gram-negative strains was weak, as has been 
reported previously [10, 48].  
Table 6. Antibacterial activities of 24, 27, and 29 against additional Gram-positive bacterial strains.  
Compound MIC [μg/mL] 
 S. aureus E. faecium 
 ATCC 29213 ATCC 43300 (MRSA) ATCC 700699 (VISA) ATCC 700221 
24 64 64 32 64 
27  8 16 8 16 
29 8 8 4 8 
MRSA, methicillin-resistant S. aureus 







Table 7. Antibacterial activities of 27 and 29 against fluoroquinolone-resistant E. coli.  
Compound MIC [μg/mL]a 








D87Y; ParC S80I 
GyrA S83L, D87N; 
ParC S80I, E84G 
ciprofloxacin 0.5 0.156 0.313 12.5 50 
27  >50 25 6.25 25 25 
29 >50 25 12.5 25 25 
aTested in the presence of efflux pump inhibitor phenylalanine-arginine β-naphthylamide (PAβN; 50 µg/mL). 
 
4. CONCLUSIONS 
Three series of structural analogs of 4,5,6,7-tetrahydrobenzo[d]thiazole-based DNA gyrase B 
inhibitors were designed, synthesized and biologically evaluated. The results of the in vitro E. 
coli and S. aureus DNA gyrase and topoisomerase IV inhibition assays showed improved 
activities of some of the type I compounds against all four enzymes, when compared to our 
previously reported series [21]. The type II and III compounds showed nanomolar E. coli DNA 
gyrase inhibition, but were generally weak S. aureus DNA gyrase and E. coli and S. aureus 
topoisomerase IV inhibitors. Importantly, the improved enzyme inhibition of the type I 
compounds also resulted in antibacterial activities against some Gram-positive strains, which 
was not seen for in the previously reported series of 4,5,6,7-tetrahydrobenzo[d]thiazoles [21]. 
Compound 29 inhibited E. coli and S. aureus DNA gyrase with IC50 values of 0.056 μM and 
3.7 μM, respectively, and showed activity against S. aureus, methicillin-resistant S. aureus, 
vancomycin-intermediate S. aureus, and E. faecium, with MICs between 4 μg/mL and 16 
μg/mL. Compound 29 thus represents a good starting point for further optimization. 
 
5. FUTURE PERSPECTIVE 
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The emerging field of multidrug resistance among bacteria calls for urgent need to develop 
novel effective antibiotics with alternative mechanisms of action, which would more likely not 
be as susceptible to the pre-existing resistance mechanisms. A lot of efforts have been made in 
the last decades to identify novel ATPase inhibitors of DNA gyrase and topoisomerase IV. 
Especially in the last few years, some of them have reached clinical trials [11], which again 
awakened optimism in these new-class antibacterials after novobiocin was withdrawn from the 
market in 2011. However, none of these compounds has so far been approved for therapeutic 
use. For sure, economical reasons hinder the development of novel antibacterials, because 
newly discovered antibiotics are usually held in reserve and prescribed only after the available 
treatment options have been exhausted. Meanwhile, in the case of first-in-class antibacterial 
agents the situation is better and the initial investment often pays off, such as in the case of 
linezolid and daptomycin [10]. One of the possible strategies for improving antibacterial 
activities of the presented 4,5,6,7-tetrahydrobenzo[d]thiazole class of GyrB inhibitors would be 
to make compounds less acidic in order to improve penetration through the bacterial cell wall. 
In addition, enzyme inhibition should be improved further by strengthening the salt bridge 
formation with Arg136 and/or cation-π interaction with Arg76 (E. coli numbering). The 
substantial amount of accumulated knowledge in the field of DNA gyrase and topoisomerase 
IV inhibitors offers opportunity to approach the development of these inhibitors with greater 
confidence in the future. Thus, clinically approved drugs from this class are hopefully not far 
away. 
6. SUMMARY POINTS 
• DNA gyrase and topoisomerase IV are important targets for designing novel 
antibacterials to overcome bacterial resistance problems.  
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• Starting from our previous series of the 4,5,6,7-tetrahydrobenzo[d]thiazole-based DNA 
gyrase B inhibitors, a structure-activity relationship of these compounds was further 
explored and up-graded. 
• Newly prepared analogs showed nanomolar enzyme inhibition of DNA gyrase and 
topoisomerase IV and the most potent was 40, with an IC50 of 0.016 μM against 
Escherichia coli DNA gyrase. 
• Compounds also showed improved in vitro antibacterial activity against Gram-positive 
strains and analog 29 possessed activity against MRSA and VISA with MICs between 
4 μg/mL and 8 μg/mL, thus representing a promising hit for further optimization studies. 
FIGURE LEGENDS 
Figure 1. DNA gyrase inhibitor novobiocin, and two novel DNA gyrase and topoisomerase IV 
inhibitors in clinical development. 
Figure 2. Representative GyrB and ParE inhibitors of natural and synthetic origins. 
Figure 3. Interactions of representative compound I of the first generation of 4,5,6,7-
tetrahydrobenzo[d]thiazole-based inhibitors in the E. coli GyrB ATP-binding site, as predicted 
by molecular docking. Hydrophobic interactions are shown in yellow, hydrogen bonds as 
dashed arrows and negative charge is shown in red. 
 
TABLE LEGENDS 
Table 1. Inhibition of Escherichia coli and Staphylococcus aureus DNA gyrase and 
topoisomerase IV by the 4,5,6,7-tetrahydrobenzo[d]thiazoles 20-41, which contain differently 
substituted pyrrole moieties (type I compounds). 
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Table 2. Hydrogen bond strengths between the pyrrole NH and the Asp73 side-chain 
carboxylate group (NH ••• OAsp73) obtained from the quantum theory of atoms in molecules 
calculations.  
Table 3. Inhibition of Escherichia coli and Staphylococcus aureus DNA gyrase and 
topoisomerase IV by the 4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine derivatives containing 
different moieties at 2-amino group (type II compounds).  
Table 4. Inhibition of Escherichia coli and Staphylococcus aureus DNA gyrase and 
topoisomerase IV by the 4,5,6,7-tetrahydrobenzo[d]thiazole-2,6-diamine derivatives containing 
the 2-(2-aminothiazol-4-yl)acetyl moiety at 2-amino group (type III compounds).  
Table 5. Minimum inhibitory concentrations of the DNA gyrase and topoisomerase IV 
inhibitors.  
Table 6. Antibacterial activities of 24, 27, and 29 against additional Gram-positive bacterial 
strains.  




The full data for the synthetic procedures and antibacterial activities of the compounds, 
inhibitory curves of in vitro enzyme inhibition for selected compounds for all enzymes, the 
NMR spectra of the representative compounds, and the molecular modeling Figures are given 
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